DECLARATION FORM ON NOTHING TO DECLARE OR NOTHING NEW TO DECLARE FOR USE IN THE INFORMATION EXCHANGE

Measure	Nothing to declare	Nothing new to declare
A, part 1		
A, part 2 (i)		
A, part 2 (ii)		
A, part 2 (iii)		
B (I)		
B (ii)	x	
C		
D		
E		x
F	x	
G		x

(Please mark the appropriate box(es) for each measure, with a tick.)

Date: 22.3.2011

State Party to the Convention: Finland

CONFEDENCE-BUILDING MEASURE A

Form A, part 1

Exchange of Data on Research Centres and Laboratories -#1

1. **Name(s) of the Facility**
   Centre for Biothreat Preparedness

2. **Responsible public or private organization or company**
   Centre for Military Medicine, Finnish Defence Forces under the Ministry of Defence and the National Institute for Health and Welfare (THL) under Ministry of Social Affairs and Health.

3. **Location and postal address**
   Tukholmankatu 8 A, FI-00290 Helsinki and Mannerheimintie 166, FI-00300 Helsinki.

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   The Centre is financed jointly by the Finnish Defence Forces and National Institute for Health and Welfare (THL).

5. **Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)**
   There are no BSL-4 units at the Centre.

6. **If no maximum containment unit, indicate highest level of protection**
   BSL-3, 120m^2

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   The Centre for Biothreat Preparedness started its activities in 2005. During 2010, the Centre developed rapid PCR detection assays for selected microbial agents.

Form A, part 1

Exchange of Data on Research Centres and Laboratories -#2

1. **Name(s) of the Facility**
   National Institute for Health and Welfare, THL (former National Public Health Institute, KTL), bacteriological and virological laboratories.

2. **Responsible public or private organization or company**
   National Institute for Health and Welfare (THL) under Ministry of Social Affairs and Health.

3. **Location and postal address**
   Mannerheimintie 166
   FI-00300 Helsinki

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Funding from the Ministry of Social Affairs and Health and large variety of external research funding.

5. **Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)**
   There are no BSL-4 laboratories or other units at this containment level.

6. **If no maximum containment unit, indicate highest level of protection**
   Three BSL-3 level laboratories. 120m^2 and 20m^2 in Helsinki, 80m^2 in Turku.

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Clinical and environmental microbiological research and reference laboratory facilities in Helsinki, Turku, Kuopio and Oulu. Working mainly with ordinary occurring endemic and epidemic bacteria and viruses with main emphases on vaccine preventable diseases, enteric pathogens, zoonoses, tuberculosis spp, enteroviruses, polioviruses, influenza (including 2009 pandemic influenza H1N1), HIV, hepatitis viruses and environmental fungi and bacteria causing human health problems. The Institute manages regional influenza and polio laboratory facilities. The Institute is in charge of biothreat preparedness in public health context. National focal point for IHR started June 2007.

Form A, part 1

Exchange of Data on Research Centres and Laboratories -#3

1. **Name(s) of the Facility**
   Yersinia Research Laboratory

2. **Responsible public or private organization or company**
   University of Helsinki
   University of Turku

3. **Location and postal address**
   Department of Bacteriology and Immunology
   Haartman Institute, University of Helsinki
   Haartmaninkatu 3
   P.O Box 21
   FI-00014 University of Helsinki
   Helsinki, Finland

   and
   Department of Medical Biochemistry and Genetics
   University of Turku
   Kiinamyllynkatu 10
   FI-20520 Turku, Finland

   Yersinia-research home page: Http://www.hi.helsinki.fi/yersinia/

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Academy of Finland, Centre for Military Medicine.

5. **Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)**
   No BSL-4 laboratories.

6. **If no maximum containment unit, indicate highest level of protection**
   Containment level BSL-2. The studied microbes have been attenuated or are avirulent.

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   The research is focused on genetics and biosynthesis of lipopolysaccharide (LPS) of *Yersinia pestis*, as well as on the role of LPS in virulence. Molecular evolution studies elucidate the relationships between the species of the genus *Yersinia.* Research work is also conducted on the identification of *Y. pestis* specific bacteriophage receptors.

Form A, part 1

Exchange of Data on Research Centres and Laboratories -#4

1. **Name(s) of the research centre and/or laboratory**
   Department of Virology

2. **Responsible public or private organization or company**
   University of Helsinki

3. **Location and postal address**
   P.O. Box 21
   Haartman Institute
   00014 University of Helsinki

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   In 2010: Funding from Helsinki University Hospital EVO-fund, University of Helsinki, National Technology Agency of Finland, Academy of Finland, Sigrid Jusélius Foundation. A project on alphavirus and flavivirus RNA detection was funded by the Centre for Military Medicine, also a project on hemorrhagic fever diagnostic by the Finnish Advisory Board for Defence.

5. **Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)**
   There are no BSL-4 laboratories.

6. **If no maximum containment unit, indicate highest level of protection**
   BSL-3, 75 m^2 (at Meilahti campus) and 100 m^2 (at Viikki campus)

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   The Helsinki University Viral Zoonoses Group (HUVZG) conducts research on virology, cell biology, ecology and epidemiology of zoonotic viruses, especially hantaviruses and certain other rodent-borne and arboviruses occurring in Northern Europe. Our research group operates within Faculty of Medicine, Haartman Institute Department of Virology, and partially at the Division of Microbiology and Immunology at the Veterinary Faculty, has a BSL-3 facility in both faculties, is connected to diagnostic laboratory of viral zoonoses in HUSLAB, Helsinki, and also acts as a WHO Collaborating Centre for Arbo- and Zoonotic Viruses. Principal investigators of the group are Alexander Plyusnin, Antti Vaheri and Olli Vapalahti.

Form A, part 1

Exchange of Data on Research Centres and Laboratories -#5

1. **Name(s) of the Facility**
   Finnish Food Safety Authority (Evira)

2. **Responsible public or private organization or company**
   Finnish Food Safety Authority under the Ministry of Agriculture and Forestry

3. **Location and postal address**
   Mustialankatu 3
   FI-00790 Helsinki

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Financing from the Ministry of Agriculture and Forestry

5. **Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)**
   None

6. **If no maximum containment unit, indicate highest level of protection**
   Six containment level 3 laboratories, total size 473,5m^2

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Diagnostics, surveillance and reference laboratory activities of animal diseases, zoonotic agents and foodborne pathogens, for example rabies, avian influenza, swine influenza (including pandemic H1N1 in pigs), Newcastle disease, foot and mouth disease, classical swine fever, anthrax, tuberculosis, verotoxic *E. coli.*

Form A, part 1

Exchange of Data on Research Centres and Laboratories -#6

1. **Name(s) of the Facility**
   Finnish Defence Forces Technical Research Centre (PVTT)

2. **Responsible public or private organization or company**
   Finnish Defence Forces Technical Research Centre (PVTT), Finnish Defence Forces under the Defence Staff

3. **Location and postal address**
   P.O. Box 5 (Paroistentie 20)
   FI-34111 Lakiala
   Finland

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Finnish Defence Forces

5. **Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)**
   No BSL-4 laboratories.

6. **If no maximum containment unit, indicate highest level of protection**
   Biosafety laboratory level BSL-2, 20 m^2. A CB-deployable laboratory has been equipped with BSL-3 glovebox.

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   The objective of the research work has been in the development of detection/identification methods for biowarfare microbes and toxins. The main activity in 2010 focused on the mapping of outdoor microbial contamination and testing and evaluation air sampling methods for airborne microbes. A deployable BC-laboratory has participated in Nordic military exercises. All biodefence research has been carried out with non-pathogenic strains, or otherwise harmless microbes.

   In addition, PVTT has been involved in developing of bio affinity molecules based detection kits for ricin toxins.

National Biological Defence Research and Development Programme Declaration

Description and Facilities

The Finnish Strategy to Secure Vital Functions of Society (2003 and 2006), as well as, The Security Strategy for Society (2010) have defined vital functions of Finnish society and established targets and development policies that guide each administrative branch of the government in dealing with its strategic tasks. These strategies called for co-operation between each government sector in combating against new threats towards society. According to the Government Reports on Finnish Security and Defence Policy of 2004 and 2009, terrorism and epidemics caused by infectious diseases were listed as key threats affecting national security.

Based on the above resolutions The Centre for Biothreat Preparedness started operations in Helsinki in May 2005. The Centre combines Finnish scientific and laboratory knowhow on biological defence, as well as on biothreat assessment and preparedness. The Centre is actively seeking domestic and international collaboration, especially in the field of rapid detection and identification methodologies of selected biological agents. The Centre is composed of two Units; the Biological Defence Unit of the Finnish Defence Forces, and the Epidemiologic Surveillance and Response Unit at THL. Scientific work is carried out in a biological safety level 3 laboratory at the THL facilities. In addition, the Centre functions within the Biomedicum Helsinki Institute, where work is carried out in close contact with the CB Defence and Environmental Health Centre of the Centre for Military Medicine.

CONFIDENCE-BUILDING MEASURE B

Form B (i)

Background information on outbreaks of reportable human infectious diseases

Disease	Number of cases per year							
	2003	2004	2005	2006	2007	2008	2009	2010
Tularaemia	823	151	62	475	403	116	405	91
Anthrax	0	0	0	-	-	-	-	-
Diphteria	0	0	0	0	0	0	0	0
Febris typhoides	6	6	8	5	10	1	4	9
Febris paratyphoides	4	9	5	5	9	11	5	8
Salmonellosis alia	2170	2248	2477	2565	2732	3 129	2330	2422
Ornithosis	0	0	0	-	-	-	-	-
Shigellosis	64	110	113	74	112	124	118	162
Cholera	1	0	1	2	0	1	1	0
Nephropatia epidemica (Puumala virus	1566	1429	2402	1890	1726	3 216	1919	1433

CONFIDENCE-BUILDING MEASURE B

Form B (ii)

Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern

Nothing to declare.

CONFIDENCE-BUILDING MEASURE C

Encouragement of publication of result and promotion of use of knowledge

Publications:

1. Leo, J.C., Elovaara, H., Bihan, D., Pugh, N., Kilpinen, S.K., Raynal, N., Skurnik, M., Farndale, R.W., and Goldman, A. 2010. A first analysis of a bacterial collagen-binding protein with the collagen Toolkits: the promiscuous binding of YadA to collagens may explain how it interferes with host processes. Infection and Immunity 78: 3226-3236.
2. Pinta, E., Duda, K.A., Hanuszkiewicz, A., Salminen, T., Bengoechea, J.A., Hyytiäinen, H., Lindner, B., Radziejewska-Lebrecht, J., Holst, O. and Skurnik, M. 2010. Characterization of the six glycosyltransferases involved in the biosynthesis of *Yersinia enterocolitica* serotype O:3 lipopolysaccharide outer core. Journal of Biological Chemistry 285:28333-28342.
3. De Castro, C., Kenyon, J.J. Cunneen, M.M., Reeves, P.R., Molinaro, A., Holst, O., and Skurnik, M. 2010. Genetic characterization and structural analysis of the O-specific polysaccharide of *Yersinia pseudotuberculosis* serotype O:1c. Innate Immunity [Epub ahead of print].
4. Huhtamo, E., Hasu, E., Uzcátegui, N.Y., Erra, E., Nikkari, S., Kantele, A., Vapalahti, O., Piiparinen, H. Early diagnosis of dengue in travelers: Comparison of a novel realtime RT-PCR, NS1 antigen detection and serology. J Clin Virol. 2010 Jan;47(1):49-53.
5. Matero, P., Hemmilä, H., Tomaso, H., Piiparinen, H., Rantakokko-Jalava, K., Nuotio L., Nikkari, S. Rapid Field Detection Assays for *Bacillus anthracis*, *Brucella spp.*, *Francisella tularensis* and *Yersinia pestis*. Clin Microbiol infect. Epub 2010 Feb 2.
6. Vartti, A-M., Aro, A.R., Jormanainen, V., Henriksson, M., Nikkari, S. Confidence in biopreparedness authorities among Finnish conscripts. Mil Med. 2010 Aug;175(8):607-9.
7. Ikonen N, Haanpää M, Rönkkö E, Lyytikäinen O, Kuusi M, Ruutu P, Kallio-Kokko H, Mannonen L, Lappalainen M, Ziegler T, Julkunen I: Genetic diversity of the 2009 pandemic influenza A(H1N1) viruses in Finland. PLoS ONE 2010;5:e13329.
8. Laine, J., Huovinen, E., Virtanen, MJ., Snellman, M., Lumio, J., Ruutu, P., Kujansuu, E., Vuento, R., Pitkänen, T., Miettinen, I., Herrala, J., Lepistö, O., Antonen, J., Helenius, J., Hänninen, M.L., Maunula, L., Mustonen, J., Kuusi, M. An extensive gastroenteritis outbreak after drinking-water contamination by sewage effluent, Finland. Epidemiol Infect 2010 Sep 15:1-9. [Epub ahead of print]
9. Rimhanen-Finne, R., Hänninen, M.L., Vuento, R., Laine, J., Jokiranta, J.T., Snellman, M., Pitkänen, T., Miettinen, I., Kuusi, M. Contaminated water caused the first outbreak of giardis in Finland, 2007: A descriptive study. Scand J Infect Dis 2010;42:613-619.
10. Rimhanen-Finne R., Järvinen A., Kuusi M., Quiambao B.P., Malbas J.F.F., Huovilainen A., Kallio-Kokko H., Vapalahti O., Ruutu P. Imported human rabies, the Philippines and Finland, 2007. Emerging Infectious Diseases 2010;16:1318-1319.
11. Huovinen E., Sihvonen L.M., Virtanen M.J., Haukka K., Siitonen A., Kuusi M. Symptoms and sources of Yersinia enterocolitica-infection: a case-control study. BMC Infectious Diseases 2010;10:122.
12. Aho, M., Lyytikainen O., Nyholm JE., Kuitunen T., Rönkkö E., Santanen R., Ziegler T., Nikkari S. Outbreak of 2009 pandemic influenza A(H1N1) in a Finnish garrison--a serological survey. Euro Surveill. 2010 Nov 11;15(45). pii: 19709.
13. Hautala T, Mähönen SM, Sironen T, Hautala N, Pääkkö E, Karttunen A, Salmela PI, Ilonen J, Vainio O, Glumoff V, Rytky S, Plyusnin A, Vaheri A, Vapalahti O, Kauma H.

Central nervous system-related symptoms and findings are common in acute Puumala hantavirus infection. Ann Med. 2010 Jul;42(5):344-51. IF 4.246.
14. Jääskeläinen AE, Sironen T, Murueva GB, Subbotina N, Alekseev AN, Castrén J, Alitalo I, Vaheri A, Vapalahti O. Tick-borne encephalitis virus in ticks in Finland, Russian Karelia and Buryatia. J Gen Virol. 2010 Nov;91(Pt 11):2706-12.
15. Kallio ER, Begon M, Henttonen H, Koskela E, Mappes T, Vaheri A, Vapalahti O. Hantavirus infections in fluctuating host populations: the role of maternal antibodies. Proc R Soc B. 2010 Dec 22;277(1701):3783-91.
16. Tersago K, Verhagen R, Vapalahti O, Heyman P, Ducoffre G, Leirs H. Hantavirus outbreak in Western Europe: reservoir host infection dynamics related to human disease patterns. Epidemiol Infect. 2010 May 10:1-10.
17. Hepojoki JM, Strandin T, Wang H, Vapalahti O, Vaheri A, Lankinen H.The Cytoplasmic Tails of Hantavirus Glycoproteins Interact with the Nucleocapsid Protein. J Gen Virol. 2010 Sep;91(Pt 9):2341-50.
18. Vapalahti K, Virtala A-M., Vaheri A, Vapalahti O. Case-control study of Puumala virus infection, Finland: smoking is a risk for hantavirus infection. Epidemiology and Infection. 2010, 138, 4: 576-584.
19. Sinisalo M, Vapalahti O, Ekblom-Kullberg S, Laine O, Mäkelä S, Rintala H, Vaheri A. Headache and low platelets in a patient with acute leukemia. J Clin Virol. 2010 Jul;48(3):159-61.
20. Franco L, Di Caro A, Carletti F, Vapalahti O, Renaudat C, Zeller H, Tenorio A. Recent expansion of dengue virus serotype 3 in West Africa. Euro Surveill. 2010 Feb 18;15(7).
21. Makary P, Kanerva M, Ollgren J, Virtanen MJ, Vapalahti O, Lyytikäinen O. Disease burden of Puumala virus infections, 1995-2008. Epidemiol Infect. 2010 Oct;138(10):1484-92.
22. Jonsson CB, Figueiredo LT, Vapalahti O. A global perspective on hantavirus ecology, epidemiology, and disease. Clin Microbiol Rev. 2010 Apr;23(2):412-41.
23. Zhang YZ, Zou Y, Fu ZF, Plyusnin A. Hantavirus infections in humans and animals, China. Emerg Infect Dis. 2010 Aug;16(8):1195-203.
24. Wang H, Alminaite A, Vaheri A, Plyusnin A. Interaction between hantaviral nucleocapsid protein and the cytoplasmic tail of surface glycoprotein Gn. Virus Res. 2010 Aug;151(2):205-12.
25. Zhang YZ, Lin XD, Shi NF, Wang W, Liao XW, Guo WP, Fan FN, Huang XM, Li MH, Li MF, Chen Y, Chen XP, Wang SB, Fu ZF, Plyusnin A. Hantaviruses in small mammals and humans in the coastal region of Zhejiang Province, China. J Med Virol. 2010 May;82(6):987-95.
26. Demina TV, Dzhioev YP, Verkhozina MM, Kozlova IV, Tkachev SE, Plyusnin A, Doroshchenko EK, Lisak OV, Zlobin VI. Genotyping and characterization of the geographical distribution of tick-borne encephalitis virus variants with a set of molecular probes. J Med Virol. 2010 May;82(6):965-76.
27. Virtanen JO, Jääskeläinen KM, Djupsjöbacka J, Vaheri A, Plyusnin A. Tula hantavirus NSs protein accumulates in the perinuclear area in infected and transfected cells. Arch Virol. 2010;155(1):117-21.
28. Laine O, Mäkelä S, Mustonen J, Huhtala H, Szanto T, Vaheri A, Lassila R, Joutsi-Korhonen L. Enhanced thrombin formation and fibrinolysis during acute Puumala hantavirus infection. Thromb Res. 2010 Aug;126(2):154-8.
29. Huiskonen JT, Hepojoki J, Laurinmäki P, Vaheri A, Lankinen H, Butcher SJ, Grünewald K. Electron cryotomography of Tula hantavirus suggests a unique assembly paradigm for enveloped viruses. J Virol. 2010 May;84(10):4889-97.
30. Hepojoki J, Strandin T, Vaheri A, Lankinen H. Interactions and oligomerization of hantavirus glycoproteins. J Virol. 2010 Jan;84(1):227-42.

Publications in finnish:

1. Kuitunen, T., Nikkari, S. CB-uhkiin varautuminen yhteistyössä siviilikumppanien kanssa. Ann Med Milit Fenn 2010;1:31-34.
2. Nikkari, S., Nuotio, L. Eläinten influenssavirukset ja niiden aiheuttama riski ihmiselle. S Lääkl 1–2/2010.
3. Nikkari, S. Biologisten aseiden uhka. Duodecim 2010;126(2):119-20.
4. Niskanen, T., Kuusi, M. Epidemian selvittäminen. Ympäristöterveyden erityistilanteet. Sosiaali- ja terveysministeriö 2010; 95-107. ISBN 978-952-00-3012-4
5. Hulkko, T., Lyytikäinen, O., Kuusi, M., Seppälä, S., Ruutu, P. Tartuntataudit Suomessa 1995-2009. Terveyden ja hyvinvoinnin laitos (THL) 2010.
6. Kurttio, P, Nikkari, S., Kuitunen, T. Tahallisesti aiheutetut NBC-tilanteet. Ympäristöterveyden erityistilanteet. Sosiaali- ja terveysministeriö 2010; 176-81. ISBN 978-952-00-3012-4
7. Kuitunen, T., Sovijärvi, A., Nikkari, S., Puolustusvoimien antama virka-apu. Ympäristöterveyden erityistilanteet. Sosiaali- ja terveysministeriö 2010; 182-84. ISBN 978-952-00-3012-4

CONFIDENCE-BUILDING MEASURE D

Form D

Active promotion of contacts

International conferences, symposia, seminars, and other similar forums are planned for the year 2011.

1. Planned international conferences, symposia, seminars, and other similar forums for exchange

1.1

- name of the conference: **9th Finnish Microbial Pathogenesis Day and Basic Microbiology Day 2011**

- arranging organizations: University of Helsinki, Finland

- time: October 19-20, 2011

- place: Haartman Institute, Haartmaninkatu 3, Helsinki, Finland

- main subject(s) for the conference: Microbial pathogenesis

- conditions for participation: free

- point of contact for further, information, registration: mikael.skurnik@helsinki.fi

CONFIDENCE-BUILDING MEASURE E

Form E

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	YES	YES	YES	NO
(b) Exports of micro-organisms* and toxins	YES	YES	YES	NO
(c) Imports of micro-organisms* and toxins	YES	YES	YES	NO

* Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.

Form E

Declaration of legislation, regulations and other measures

Additional information

Finland's legislation on biological weapons is based on the Biological Weapons Act 257/1975 and Decree 258/1975. Corresponding penal provisions were included in the Penal Code, chapter 11, section 7 b (Breach of the prohibition of biological weapons), with amendment 17/2003. Penal Code (39/1889) chapter 11, section 1 (War Crime), chapter 5, section 3 (Complicity in an offence) and section 6 (Abetting), chapter 34, sections 4 (Health endangerment) and 5 (Aggravated health endangerment), and chapter 34 a (Terrorist offences) are also applicable.

Exports of micro-organisms and toxins are regulated by the Act on the Control of Export of Dual-Use Goods (562/1996, as amended by Acts 891/2000, 884/2001 and 581/2003), Government Decree on the Control of Export of Dual-Use Goods (924/2000 as amended by Decree 924/2000) and EC Council Regulation 1334/2000. Corresponding penal provisions were incorporated in the Penal Code (39/1889), chapter 46, sections 1-3 by Acts 769/1990, 1522/1994 and 706/1997. Since 2003, the authority responsible for export controls of micro-organisms and toxins is the Ministry for Foreign Affairs (Export Control Unit).

Imports of micro-organisms and toxins are regulated by the Biological Weapons Act 257/1975 and Decree 258/1975. Transports of micro-organisms and toxins are also regulated by the EC Council Directives 94/55/EEC and 96/49/EEC, the Communicable Diseases Act 583/1986 (as amended), section 33; Communicable Diseases Decree 786/1986 (as amended); Act on the Transport of Dangerous Goods (719/1994 as amended) and related decrees, Act on Protecting Plant Health (702/2003), section 7, and related decrees, Act on Animal Diseases (55/1980 as amended) and related decrees, Act on Veterinary Border Control (1192/1996 as amended) and related decrees. The corresponding penal provisions are included in the Penal Code (39/1889 as amended), chapter 44, section 2 (Health protection violation), chapter 44, section 13 (Transport of dangerous substances offence) and chapter 46, section 4 (Smuggling).

CONFIDENCE-BUILDING MEASURE F

Form F

Declaration of past activities in offensive and/or defensive biological research and development programmes

Nothing to declare.

CONFIDENCE-BUILDING MEASURE G

Form G

Declaration of vaccine production facilities

There are no vaccine production facilities in Finland.